Heart Valve Disease

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Heart Valve Disease

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease 11 14 63 16 71
Valvular Heart Disease 11 14 75
Heart Valve Diseases 41 43 33
Valvular Heart Diseases 53
Heart Valve Prolapse 43


External Ids:

Disease Ontology 11 DOID:4079
NCIt 49 C45525
SNOMED-CT 68 368009 398995000
UMLS 71 C0018824 C0079485

Summaries for Heart Valve Disease

MedlinePlus: 41 What are heart valve diseases? Heart valve disease happens when one or more of your heart valves don't work well. Your heart has four valves: the tricuspid, pulmonary, mitral, and aortic valves. The valves have flaps that open and close. The flaps make sure that blood flows in the right direction through your heart and to the rest of your body. When your heart beats, the flaps open to let blood through. Between heartbeats they close to stop the blood from flowing backwards. If one or more of your heart valves doesn't open or close correctly, it can affect your blood flow and strain your heart. Fortunately, treatment helps most valve diseases. What are the types of heart valve diseases? Heart valves can have three basic kinds of problems: Regurgitation, or backflow, happens when the flaps of a valve don't close tightly. This allows the blood to leak backwards. A common cause of regurgitation is prolapse, where the flaps of the valve flop or bulge back. Prolapse most often affects the mitral valve. Stenosis happens when the flaps of a valve become thick, stiff, or stuck together. This prevents the heart valve from opening all the way. Not enough blood can pass through the valve. Aortic valve stenosis is a common type of stenosis. It affects the valve that controls blood flow into the large artery that carries blood out of the heart to the body. Atresia happens when a heart valve did not form properly and does not have an opening for blood to pass through. Sometimes a valve can have both regurgitation and stenosis. What causes heart valve diseases? Some people are born with heart valve disease. This is called congenital heart valve disease. It can happen alone or along with other congenital heart defects. Heart valve disease can also develop over time as you get older or have certain conditions that affect the heart. Who is more likely to develop heart valve diseases? Your chance of having heart valve disease is higher if: You are older. With age, the heart valves can become thick and stiff. You have or have had other conditions that affect your heart and blood vessels. These include: Rheumatic fever. An untreated strep throat can become rheumatic fever, which can harm the heart valves. The damage may not show up for years. Today, most people take antibiotics to cure strep throat before it can cause heart valve damage. Endocarditis. This is a rare infection in the lining of the heart and heart valves. It is usually caused by bacteria in the bloodstream. A heart attack. Heart failure. Coronary artery disease, especially when it affects the aorta (the large artery that carries blood from the heart to the body). High blood pressure. High blood cholesterol. Diabetes. Obesity and overweight. Lack of physical activity. A family history of early heart disease: A father or brother who had heart disease younger than 55. A mother or sister who had heart disease younger than 65. You were born with an aortic valve that wasn't formed right. Sometimes this will cause problems right away. Other times, the valve may work well enough for years before causing problems. What are the symptoms of heart valve diseases? Many people live their whole lives with a heart valve that doesn't work perfectly and never have any problems. But heart valve disease may get worse slowly over time. You may develop signs and symptoms, such as: Shortness of breath (feeling like you can't get enough air) Fatigue Swelling in your feet, ankles, abdomen (belly), or the veins in your neck Chest pain when you're physically active Arrhythmia, a problem with the rate or rhythm of your heartbeat Dizziness or fainting If you don't get treatment for heart valve disease, the symptoms and strain on your heart may keep getting worse. What other problems can heart valve diseases cause? When the valves don't work well, your heart has to pump harder to get enough blood out to the body. Without treatment, this extra workload on your heart can lead to: Heart failure Stroke Blood clots Sudden cardiac arrest or death How is heart valve disease diagnosed? Your health care provider may listen to your heart with a stethoscope and hear that your heart makes abnormal sounds, such as a click or a heart murmur. These sounds may mean a valve isn't working normally. The provider will usually refer you to a cardiologist, a doctor who specializes in heart diseases. The doctor will also listen to your heart and will do a physical exam. You will also likely need to have one or more heart tests. What are the treatments for heart valve diseases? Most heart valve problems can be treated successfully. Treatment may include: Medicines to control your symptoms and keep your heart pumping well Heart-healthy lifestyle changes to treat other related heart conditions Surgery to repair or replace a valve It's possible that you may need surgery, even if you don't have symptoms. Fixing the valve can help can prevent future heart problems. There are many ways to do heart valve surgery. You and your doctor can decide what's best for you, based on your valve problem and general health. Heart valve repair surgery has fewer risks than heart valve replacement. So, when repair is possible, it's preferred over valve replacement. In some cases, valve replacement is necessary. There are 2 types of replacement valves: Biologic valves made from pig, cow, or human tissue. These valves tend to wear out after 10 to 15 years, but some may last longer. Mechanical (human-made) valves usually don't wear out. But with a mechanical valve, you usually have to take blood thinners for the rest of your life to prevent blood clots. And your risk of endocarditis (a heart infection) is higher than with a biologic valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Heart Valve Disease, also known as valvular heart disease, is related to rheumatic heart disease and tricuspid valve stenosis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Heart Valve Disease is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and miRNAs involvement in the immune response in sepsis. The drugs Acetylcysteine and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotype is homeostasis/metabolism.

PubMed Health : 63 Heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves. These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Disease Ontology: 11 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

Wikipedia: 75 Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Related Diseases for Heart Valve Disease

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 608)
# Related Disease Score Top Affiliating Genes
1 rheumatic heart disease 32.4 NPPB ELN ACE
2 tricuspid valve stenosis 32.3 SERPINA3 NPPB
3 tricuspid valve disease 32.2 REN NR3C2 NPPB FBN1 CRP ACE
4 dilated cardiomyopathy 31.5 SERPINA3 REN NR3C2 NPPB NPPA MIR499A
5 pericarditis 31.2 NPPB CRP ACE
6 aortic valve insufficiency 31.1 REN NPPB FBN1 ELN CRP ACE
7 mitral valve stenosis 31.1 SERPINA3 REN NR3C2 NPPB NPPA CRP
8 infective endocarditis 31.1 NPPB CRP CNMD ACE
9 mitral valve insufficiency 31.0 REN NR3C2 NPPB NPPA MIR423 FBN1
10 arteries, anomalies of 31.0 SERPINA3 REN MIR499A MIR423 MIR29B1 MIR21
11 tricuspid valve insufficiency 30.9 REN NR3C2 NPPB FBN1 CRP ACE
12 kawasaki disease 30.9 NPPB ELN CRP
13 aortic valve disease 2 30.9 SERPINA3 REN NPPB NPPA MIR423 MIR29B1
14 constrictive pericarditis 30.9 REN NPPB CRP ACE
15 lipoprotein quantitative trait locus 30.9 SERPINA3 REN NPPB NPPA MIR499A MIR423
16 pericardial effusion 30.9 REN NPPB NPPA CRP ACE
17 kidney disease 30.9 REN NR3C2 NPPB NPPA MIR21 MIR199A1
18 systemic scleroderma 30.8 MIR21 FBN1 CRP ACE
19 stroke, ischemic 30.8 SERPINA3 REN NR3C2 NPPB NPPA MIR21
20 peripheral vascular disease 30.8 SERPINA3 REN MIR126 CRP ACE
21 migraine with or without aura 1 30.8 SERPINA3 REN CRP APOH ACE
22 nonbacterial thrombotic endocarditis 30.8 CRP APOH
23 aortic valve disease 1 30.8 REN NPPB MIR423 MIR29B1 MIR21 MIR204
24 central sleep apnea 30.8 REN NPPB CRP ACE
25 sleep apnea 30.8 REN NPPB CRP ACE
26 cardiac tamponade 30.8 REN NPPB CRP ACE
27 third-degree atrioventricular block 30.8 REN NPPB CRP ACE
28 ventricular septal defect 30.7 NPPB NPPA MIR499A MIR423 MIR199A1
29 hypersensitivity vasculitis 30.7 SERPINA3 REN CRP ACE
30 mitral valve disease 30.7 SERPINA3 REN NR3C2 NPPB NPPA MIR423
31 aortic aneurysm 30.7 REN MIR29B1 MIR21 MIR126 FBN1 ELN
32 apnea, obstructive sleep 30.7 REN NR3C2 NPPB CRP ACE
33 deficiency anemia 30.7 SERPINA3 REN MIR126 CRP ACE
34 libman-sacks endocarditis 30.7 CRP APOH
35 lipid metabolism disorder 30.7 SERPINA3 REN MIR21 MIR199A1 MIR126 CRP
36 orthostatic intolerance 30.6 REN MIR423 FBN1 ELN CRP ACE
37 mediastinum teratoma 30.6 CRP ACE
38 cardiogenic shock 30.6 NPPB NPPA
39 pulmonary valve insufficiency 30.6 REN NPPB FBN1 CRP ACE
40 atrioventricular block 30.6 NPPB CRP ACE
41 eclampsia 30.6 REN APOH ACE
42 hypertrophic cardiomyopathy 30.6 SERPINA3 REN NR3C2 NPPB NPPA MIR499A
43 alcoholic cardiomyopathy 30.6 REN NPPB ACE
44 right bundle branch block 30.6 NPPB CRP ACE
45 inferior myocardial infarction 30.6 NPPB ACE
46 decubitus ulcer 30.6 MIR21 ELN CRP
47 pulmonary hypertension 30.6 REN NPPB NPPA MIR21 MIR204 ELN
48 syphilis 30.6 CRP APOH ACE
49 henoch-schoenlein purpura 30.6 SERPINA3 CRP ACE
50 sleep disorder 30.5 REN CRP ACE

Graphical network of the top 20 diseases related to Heart Valve Disease:

Diseases related to Heart Valve Disease

Symptoms & Phenotypes for Heart Valve Disease

UMLS symptoms related to Heart Valve Disease:

angina pectoris; chest pain; edema; undiagnosed heart murmur

MGI Mouse Phenotypes related to Heart Valve Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.47 ACE APOH CNMD CRP CTF1 ELN

Drugs & Therapeutics for Heart Valve Disease

PubMed Health treatment related to Heart Valve Disease: 63

Currently, no medicines can cure heart valve disease . However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve. The goals of treating heart valve disease might include: Preventing, treating, or relieving the symptoms of other related heart conditions. Protecting heart valves from further damage. Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Remifentanil Approved Phase 4 132875-61-7 60815
Etomidate Approved Phase 4 33125-97-2 667484
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
Dabigatran Approved, Investigational Phase 4 211914-51-1 216210
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Vecuronium Approved, Investigational Phase 4 50700-72-6, 86029-43-8 39765 39764
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Simendan Investigational Phase 4 131741-08-7
32 Antioxidants Phase 4
33 Protective Agents Phase 4
34 Chrysarobin Phase 4
35 Antiviral Agents Phase 4
36 Anti-Infective Agents Phase 4
37 Expectorants Phase 4
38 Antidotes Phase 4
39 N-monoacetylcystine Phase 4
40 Respiratory System Agents Phase 4
41 Adrenergic beta-Antagonists Phase 4
42 Adrenergic beta-1 Receptor Antagonists Phase 4
43 Adrenergic Antagonists Phase 4
44 Sympatholytics Phase 4
45 Platelet Aggregation Inhibitors Phase 4
46 Phosphodiesterase Inhibitors Phase 4
47 Vitamin B1 Phase 4
48 Phosphodiesterase 3 Inhibitors Phase 4
49 Thiamin Phase 4
50 Dsuvia Phase 4

Interventional clinical trials:

(show top 50) (show all 365)
# Name Status NCT ID Phase Drugs
1 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
2 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
3 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
4 Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement Unknown status NCT03440268 Phase 4 N Acetyl Cysteine;Placebos
5 Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Out-patients Undergoing Diagnostic Trans-esophageal Echocardiography: A Randomized Controlled Trial Completed NCT02867930 Phase 4 Dexmedetomidine;Ketofol(ketamine+propofol)
6 The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting Completed NCT01210976 Phase 4 levosimendan;placebo
7 Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial Completed NCT01384643 Phase 4 Propofol
8 Sildenafil for Improving Outcomes After Valvular Correction Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
9 Effect of Propofol and Sevoflurane on Serum CD39 and CD73 Level After Open Heart Surgery With Cardiopulmonary Bypass Completed NCT02136979 Phase 4 Propofol;Sevoflurane
10 Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery Completed NCT03280745 Phase 4 Hypertonic saline;0.9% saline
11 The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone. Completed NCT01495949 Phase 4 etomidate;thiopentone
12 The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
13 Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery Completed NCT01174719 Phase 4 volume replacement;Humanalbumin 5%
14 Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial. Completed NCT01477151 Phase 4 Volatile anesthetic
15 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
16 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
17 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
18 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Completed NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
19 Ultrasound Guided Repeated Bilateral Transversus Thoracis Muscle Plane Block Via Catheter and Postoperative Pain in Cardiac Surgery Recruiting NCT04916418 Phase 4 Placebo;Ropivacaine
20 Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery: Randomized Clinical Trial Recruiting NCT05079672 Phase 4 Dexmedetomidine;0,9% Saline
21 Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University: Randomized Prospective Comparative Study Active, not recruiting NCT04223219 Phase 4 Fentanyl;Fentanyl, Propofol;Dexmedetomidine, Ketamine, Magnesium sulfate
22 Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section Not yet recruiting NCT05110482 Phase 4 Syntocinon;Carbetocin
23 Sugammadex Titration for Reversal of Rocuronium or Vecuronium in Cardiac Surgery Patients Not yet recruiting NCT05246397 Phase 4 Sugammadex administration
24 Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial Withdrawn NCT00187304 Phase 4
25 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
26 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
27 Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair Completed NCT02084069 Phase 3 Atorvastatin
28 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
29 Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery Completed NCT05223361 Phase 3 Six percent hydroxy ethyl starch 130/0.4;Ringer lactate
30 Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial Completed NCT02833948 Phase 3 Acetylsalicylic acid;Clopidogrel;Rivaroxaban
31 Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery Completed NCT02237495 Phase 2, Phase 3 dexmedetomidine;placebo
32 Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR) Completed NCT02679261 Phase 3 Atorvastatin;Placebo
33 An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 3 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) Recruiting NCT05143177 Phase 2, Phase 3 Evogliptin;Placebo
34 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Recruiting NCT04408430 Phase 2, Phase 3
35 Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery Terminated NCT00250965 Phase 3 intravenous magnesium
36 Clinical Trial Comparing a Conventional Median Sternotomy Versus a Minimally Invasive Technique for Aortic Valvular Replacement in Adults Terminated NCT00221663 Phase 2, Phase 3
37 Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Terminated NCT03566303 Phase 2, Phase 3 Rivaroxaban 15 mg;Warfarin
38 Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (the PRINT II Study): a Randomized Controlled, Non-inferiority Trial Comparing 4-weekly With 12-weekly Testing and Dose-assessment Withdrawn NCT01654042 Phase 3
39 Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass, a Single Center's Experience Unknown status NCT00921596 Phase 1, Phase 2
40 Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study Unknown status NCT02917525 Phase 2
41 A Prospective, Randomized, Multicenter Clinical Study on the High Vacuum Body Cavity Drainage Systems Following Open Heart Surgery Completed NCT00581399 Phase 2
42 Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery Completed NCT01348074 Phase 2 Double dose
43 CopenHeartVR - A Randomized Clinical Trial Investigating the Effect of Integrated Rehabilitation Versus Usual Care Without Physical Exercise After Heart Valve Surgery. Completed NCT01558765 Phase 2
44 A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER Completed NCT02303795 Phase 2 Rivaroxaban;Warfarin
45 Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial Completed NCT01681095 Phase 2 Custodiol HTK;Cold Blood Cardioplegia
46 N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement. Completed NCT01704482 Phase 2 N-acetylcysteine;placebo
47 The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study Completed NCT02479581 Phase 2
48 Cytokine Clearance With Cytoabsorbant Device During Cardiac Bypass: a Pilot Study Completed NCT02775123 Phase 1, Phase 2
49 Nitric Oxide Supplementation to the Extracorporeal Circulation Line as a Method of Nephroprotection in Cardiac Surgery Completed NCT03527381 Phase 1, Phase 2 Nitric Oxide
50 A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin Completed NCT00356759 Phase 2 Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Genetic Tests for Heart Valve Disease

Anatomical Context for Heart Valve Disease

Organs/tissues related to Heart Valve Disease:

MalaCards : Heart, Lung, Bone, Kidney, Brain, Whole Blood, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Atrioventricular Valves Atrioventricular Valve Cells Affected by disease
2 Heart Semilunar Valves Semilunar Valve Cells Affected by disease

Publications for Heart Valve Disease

Articles related to Heart Valve Disease:

(show top 50) (show all 7517)
# Title Authors PMID Year
Clinical Features and Survival Analysis of Patients after Mechanical Heart Valve Replacement, with an Emphasis on Prosthetic Valve Thrombosis. 62 41
36453764 2022
Clinical characteristics and risk factors for rebleeding in uremic patients with obscure gastrointestinal bleeding undergoing deep enteroscopy: A multi-center retrospective study in Taiwan. 62 41
36449459 2022
Short-Term Results on Leaflet Mobility in Patients Undergoing Rheumatic Mitral Valve Repair With an Efficient 4-Step Commissuroplasty Technique. 41
36450146 2022
A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. 53 62
20436747 2010
Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? 53 62
18307738 2008
Predictive value of heart-type fatty acid-binding protein for left ventricular remodelling and clinical outcome of hypertensive patients with mild-to-moderate aortic valve diseases. 53 62
17392813 2007
[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]. 53 62
17339740 2007
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 53 62
17345160 2007
Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. 53 62
16043943 2005
[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]. 53 62
16029597 2005
Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. 53 62
15721858 2005
Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. 53 62
14973795 2004
Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. 53 62
14674704 2003
Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. 53 62
14677016 2003
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. 53 62
14608520 2003
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. 53 62
12761331 2003
Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease. 53 62
12630582 2003
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. 53 62
12466135 2002
Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid. 53 62
12270761 2002
Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. 53 62
9286500 1997
Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. 53 62
9104915 1997
Elevated anticardiolipin antibodies in a patient with vibration-white-finger, valvular heart disease and psoriatic arthritis. 53 62
8467615 1993
Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. 53 62
8451600 1993
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 53 62
1611635 1992
Atrial natriuretic peptide: pathophysiological considerations. 53 62
1534550 1992
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 53 62
1933972 1991
Lack of association between anticardiolipin antibodies and heart valve disease in Chinese patients with systemic lupus erythematosus. 53 62
1975008 1990
Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring. 62
36202174 2023
Clinical features, myocardial strain and tissue characteristics of heart failure with preserved ejection fraction in patients with obesity: A prospective cohort study. 62
36386034 2023
Anterior-Posterior versus anterior-lateral electrodes position for electrical cardioversion of atrial fibrillation: A meta-analysis of randomized controlled trials. 62
36304256 2022
Red cell distribution width as a prognosticator in patients with heart failure. 62
36460487 2022
Emerging role of pericytes in therapy of cardiovascular diseases. 62
36411618 2022
Managing Diastolic Dysfunction Perioperatively. 62
36473032 2022
Hybrid heart valves with VEGF-loaded zwitterionic hydrogel coating for improved anti-calcification and re-endothelialization. 62
36278142 2022
Cellular Landscapes of Nondiseased Human Cardiac Valves From End-Stage Heart Failure-Explanted Heart. 62
36200446 2022
Valvular heart diseases in immigrants and Swedish-born individuals: a national cohort study. 62
35792712 2022
Crossing the Boundaries of Treatment of Valvular Heart Disease in Patients With Liver Cirrhosis. 62
36155717 2022
Advances in Neurocardiology: Focus on Anticoagulation for Valvular Heart Disease With and Without Atrial Fibrillation. 62
36337056 2022
The importance of big databases in understanding valvular heart disease. 62
36464940 2022
Maternal mortality due to valvular heart disease: a population-based study in Turkey. 62
34988858 2022
Evolution of non-fatal burden estimates for cardiovascular disease in Australia: a comparison of national and state-wide methodology of burden of disease. 62
36395787 2022
Surgery in severe valvular heart diseases: when it is too late, too early or right on time? 62
36349942 2022
The leaflet-annulus index in canine myxomatous mitral valve disease. 62
36029573 2022
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program. 62
35801621 2022
Cardiovascular CT, MRI, and PET/CT in 2021: Review of Key Articles. 62
36378032 2022
Hedinger Syndrome with Intraoperative Carcinoid Crisis - Understanding the Pathophysiology for a Successful Management. 62
34673518 2022
Major adverse cardiac events after elective infrarenal endovascular aortic aneurysm repair. 62
35714892 2022
Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations. 62
35359027 2022
Safety and usefulness of left ventricular endomyocardial biopsy in new- onset acute heart failure requiring mechanical support by an Impella® device. 62
35944774 2022
MitraClip: a review of its current status and future perspectives. 62
36469300 2022

Variations for Heart Valve Disease

Expression for Heart Valve Disease

Search GEO for disease gene expression data for Heart Valve Disease.

Pathways for Heart Valve Disease

Pathways related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 10.92 MIR21 MIR199A1 MIR126

GO Terms for Heart Valve Disease

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 SERPINA3 REN NPPB NPPA FBN1 ELN
2 RISC complex GO:0016442 9.86 MIR126 MIR146A MIR199A1 MIR204 MIR21 MIR29B1
3 extracellular space GO:0005615 9.72 SERPINA3 REN NPPB NPPA MIR423 MIR29B1

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 10.18 MIR499A MIR423 MIR29B1 MIR21 MIR204 MIR199A1
2 regulation of blood pressure GO:0008217 10.06 REN NPPB NPPA ACE
3 positive regulation of apoptotic process GO:0043065 10.05 MIR29B1 MIR21 MIR204 MIR146A ACE
4 negative regulation of gene expression GO:0010629 10.04 MIR29B1 MIR21 MIR199A1 MIR146A ACE
5 negative regulation of angiogenesis GO:0016525 9.92 APOH CNMD MIR146A MIR21 NPPB
6 blood vessel diameter maintenance GO:0097746 9.89 NPPB NPPA ACE
7 negative regulation of inflammatory response GO:0050728 9.84 MIR204 MIR199A1 MIR146A MIR126
8 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.73 MIR499A MIR21 MIR146A
9 negative regulation of endothelial cell proliferation GO:0001937 9.73 MIR21 MIR146A CNMD APOH
10 positive regulation of potassium ion export across plasma membrane GO:1903766 9.69 NPPA MIR21
11 positive regulation of vascular endothelial cell proliferation GO:1905564 9.65 MIR499A MIR21 MIR126
12 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.61 MIR146A MIR21 MIR499A
13 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.58 MIR21 MIR146A MIR126
14 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR29B1 MIR21
15 negative regulation of metallopeptidase activity GO:1905049 9.52 MIR199A1 MIR29B1
16 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.46 MIR29B1 MIR21 MIR204 MIR146A
17 negative regulation of matrix metallopeptidase secretion GO:1904465 9.13 MIR29B1 MIR199A1 MIR146A
18 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.1 MIR499A MIR29B1 MIR21 MIR204 MIR146A MIR126

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 MIR499A MIR29B1 MIR21 MIR204 MIR199A1 MIR146A
2 hormone receptor binding GO:0051427 9.46 NPPB NPPA
3 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR499A MIR423 MIR29B1 MIR21 MIR204 MIR199A1

Sources for Heart Valve Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....